Related Experiment Video
Updated: Aug 9, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Epigenetic therapy with decitabine for myelodysplasia and leukemia
1Leyenburg Hospital, Department of Haematology, Leyweg 275, 2545 CH, The Hague, The Netherlands. p.wijermans@hagaziekenhuis.nl
Abstract:
New therapeutic approaches are being developed for the treatment of cancer patients. Increasingly, drugs are being produced based on new insight into the intracellular processes in the cancer cell. Recently the typical epigenetic changes in the tumor cell have been considered as a therapeutic target. Several drugs have shown potential epigenetic activity. Decitabine (5-aza-2 -deoxycytidine, Dacogen) is one of the drugs that is able to induce changes in the methylation status of DNA. In this article the authors present an overview of this drug with regard to the chemistry, pharmacokinetics and the data that support its role as the new therapeutic agent in leukemia and myelodysplastic syndrome.
Insights
Decitabine, a DNA methylation inhibitor, offers a new therapeutic strategy for cancer. This drug shows promise for treating leukemia and myelodysplastic syndromes by targeting epigenetic changes in tumor cells.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Cancer treatment is evolving with new drugs targeting intracellular processes.
- Epigenetic modifications in tumor cells are emerging as a key therapeutic target.
- Decitabine (5-aza-2 -deoxycytidine) is an epigenetic drug influencing DNA methylation.
Purpose of the Study:
- To provide an overview of Decitabine.
- To discuss the chemistry and pharmacokinetics of Decitabine.
- To review data supporting Decitabine's efficacy in leukemia and myelodysplastic syndrome.
Main Methods:
- Literature review of Decitabine's properties.
- Analysis of clinical data for Decitabine in hematological malignancies.
- Pharmacokinetic and chemical profile assessment.
Main Results:
- Decitabine demonstrates significant epigenetic activity by altering DNA methylation.
- Clinical data suggest Decitabine is a viable therapeutic agent for specific leukemias and myelodysplastic syndromes.
- The drug's chemistry and pharmacokinetic profile are well-characterized.
Conclusions:
- Decitabine represents a novel epigenetic therapy for cancer.
- Its ability to modify DNA methylation supports its use in hematological malignancies.
- Further research confirms Decitabine's role in treating leukemia and myelodysplastic syndrome.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Gene Therapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...